EIKCS 2021: Biomarkers for kidney cancer

Dr Thomas Powles from St Barts Hospital, London spoke about the work looking for tissue-based biomarkers for renal cell carcinoma (RCC) for potential use in the clinic at the European International Kidney Cancer Symposium (EIKC) 2021 Virtual Meeting. To date, the only biomarker that is used is one to predict survival (prognosis) based on the […]

read more

ASCO GU 2021: Comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for advanced papillary kidney cancer

A gene called MET codes for a protein called MET tyrosine protein kinase (also called hepatocyte growth factor receptor), which¬† stimulates the growth and development of tumours. MET tyrosine protein kinase is a key driver of the growth and development of papillary renal cell carcinoma (pRCC). In this study presented at the American Society of […]

read more

Savolitinib shows promise in first-in-human phase 1 study in solid tumours

Results from a first-in-human phase 1 study of savolitinib in 48 patients with locally advanced or metastatic solid tumours was published in Clinical Cancer Research last month. Savolitinib is a selective MET inhibitor. In the study, the maximum tolerated dose was found to be 800 mg daily, and the recommended dose for phase 2 testing […]

read more

Current treatment of advanced papillary renal cell carcinoma

Despite significant improvements in the treatment outcomes of clear cell renal cell carcinoma (RCC), advanced/metastatic papillary RCC continues to have limited treatment options and there is clearly an unmet need. However, it is hoped that an optimal first-line treatment for papillary RCC will be identified in the next few years through the use of molecular […]

read more
Showing all 4 results